Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 91 | 2024 | 1269 | 15.050 |
Why?
|
Receptors, Antigen, T-Cell | 56 | 2024 | 2540 | 7.850 |
Why?
|
T-Lymphocytes | 83 | 2024 | 10182 | 6.350 |
Why?
|
Hematologic Neoplasms | 14 | 2024 | 1831 | 3.690 |
Why?
|
Antigens, CD19 | 20 | 2022 | 380 | 3.590 |
Why?
|
Antigens, Neoplasm | 15 | 2024 | 1987 | 2.060 |
Why?
|
Glioblastoma | 10 | 2024 | 3481 | 1.880 |
Why?
|
Multiple Myeloma | 15 | 2023 | 5180 | 1.880 |
Why?
|
Neoplasms | 28 | 2024 | 21672 | 1.880 |
Why?
|
B-Cell Maturation Antigen | 7 | 2023 | 140 | 1.880 |
Why?
|
Genetic Engineering | 9 | 2022 | 952 | 1.790 |
Why?
|
Immunotherapy | 19 | 2021 | 4440 | 1.630 |
Why?
|
Lymphoma, B-Cell | 5 | 2024 | 931 | 1.450 |
Why?
|
Recombinant Fusion Proteins | 10 | 2019 | 3772 | 1.230 |
Why?
|
Neurotoxicity Syndromes | 5 | 2023 | 290 | 1.150 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2022 | 1596 | 1.100 |
Why?
|
Antibodies, Bispecific | 2 | 2019 | 164 | 1.060 |
Why?
|
Antigen-Presenting Cells | 7 | 2020 | 973 | 1.050 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2022 | 1519 | 0.960 |
Why?
|
Receptors, Antigen | 2 | 2014 | 53 | 0.950 |
Why?
|
Tumor Microenvironment | 11 | 2023 | 3584 | 0.900 |
Why?
|
Lymphoma | 3 | 2022 | 1873 | 0.850 |
Why?
|
4-1BB Ligand | 2 | 2020 | 29 | 0.840 |
Why?
|
Transduction, Genetic | 3 | 2020 | 913 | 0.840 |
Why?
|
Bone Marrow Neoplasms | 1 | 2022 | 104 | 0.820 |
Why?
|
Cytotoxicity, Immunologic | 6 | 2021 | 1368 | 0.810 |
Why?
|
RNA, Small Cytoplasmic | 1 | 2020 | 21 | 0.750 |
Why?
|
Humans | 160 | 2024 | 744220 | 0.740 |
Why?
|
Lymphoma, Follicular | 2 | 2022 | 435 | 0.730 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2023 | 260 | 0.720 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2019 | 40 | 0.710 |
Why?
|
Lymphocyte Activation | 14 | 2021 | 5523 | 0.700 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2019 | 233 | 0.690 |
Why?
|
Research Personnel | 1 | 2024 | 573 | 0.670 |
Why?
|
Pancytopenia | 1 | 2019 | 104 | 0.660 |
Why?
|
Lentivirus | 2 | 2022 | 501 | 0.650 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 1378 | 0.620 |
Why?
|
T-Cell Antigen Receptor Specificity | 4 | 2019 | 87 | 0.610 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 207 | 0.600 |
Why?
|
Brain Neoplasms | 7 | 2021 | 8860 | 0.570 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 1 | 2016 | 67 | 0.550 |
Why?
|
Lymphoma, T-Cell | 1 | 2018 | 299 | 0.540 |
Why?
|
Immunity, Cellular | 3 | 2020 | 1607 | 0.530 |
Why?
|
Central Nervous System Neoplasms | 2 | 2022 | 895 | 0.500 |
Why?
|
Immunologic Factors | 2 | 2020 | 1582 | 0.490 |
Why?
|
Biological Products | 2 | 2022 | 860 | 0.480 |
Why?
|
Autoimmune Diseases | 3 | 2020 | 2136 | 0.470 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2021 | 3557 | 0.450 |
Why?
|
Pyrazoles | 5 | 2022 | 1973 | 0.450 |
Why?
|
Flow Cytometry | 5 | 2021 | 5974 | 0.420 |
Why?
|
Virus Diseases | 2 | 2020 | 711 | 0.420 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2023 | 4385 | 0.410 |
Why?
|
Animals | 40 | 2023 | 168788 | 0.410 |
Why?
|
Pyrimidines | 5 | 2022 | 2940 | 0.400 |
Why?
|
Pleural Neoplasms | 2 | 2014 | 607 | 0.390 |
Why?
|
Adaptive Immunity | 1 | 2016 | 713 | 0.380 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2024 | 9230 | 0.370 |
Why?
|
Pancreatic Neoplasms | 3 | 2023 | 5257 | 0.360 |
Why?
|
Mesothelioma | 2 | 2014 | 818 | 0.360 |
Why?
|
Receptors, Immunologic | 4 | 2017 | 1423 | 0.350 |
Why?
|
Cell Line, Tumor | 14 | 2023 | 16687 | 0.340 |
Why?
|
Skin | 2 | 2019 | 4363 | 0.340 |
Why?
|
Mice, Inbred NOD | 5 | 2019 | 1877 | 0.330 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2022 | 3523 | 0.330 |
Why?
|
B-Lymphocytes | 2 | 2020 | 4665 | 0.330 |
Why?
|
Cancer Vaccines | 2 | 2016 | 1024 | 0.330 |
Why?
|
K562 Cells | 3 | 2020 | 634 | 0.330 |
Why?
|
Echovirus Infections | 1 | 2008 | 7 | 0.320 |
Why?
|
Enterovirus B, Human | 1 | 2008 | 52 | 0.310 |
Why?
|
Cytokines | 7 | 2023 | 7326 | 0.310 |
Why?
|
Leukemia, B-Cell | 2 | 2019 | 86 | 0.300 |
Why?
|
Mice | 19 | 2023 | 81178 | 0.290 |
Why?
|
Cell Proliferation | 7 | 2019 | 10480 | 0.280 |
Why?
|
Clinical Trials as Topic | 8 | 2023 | 7908 | 0.280 |
Why?
|
Single-Cell Analysis | 3 | 2021 | 2183 | 0.280 |
Why?
|
Interleukin-7 | 2 | 2023 | 142 | 0.280 |
Why?
|
Adoptive Transfer | 2 | 2022 | 844 | 0.280 |
Why?
|
Tumor Escape | 2 | 2021 | 349 | 0.270 |
Why?
|
Anaphylaxis | 1 | 2013 | 746 | 0.270 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2019 | 2988 | 0.260 |
Why?
|
Signal Transduction | 6 | 2021 | 23404 | 0.260 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2024 | 4477 | 0.240 |
Why?
|
GPI-Linked Proteins | 3 | 2017 | 434 | 0.240 |
Why?
|
T-Lymphocyte Subsets | 4 | 2017 | 1838 | 0.240 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2727 | 0.240 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 5529 | 0.240 |
Why?
|
Immunity, Innate | 1 | 2016 | 2958 | 0.230 |
Why?
|
Bone Marrow | 4 | 2022 | 2944 | 0.230 |
Why?
|
Virus Latency | 2 | 2023 | 358 | 0.230 |
Why?
|
Immune Tolerance | 4 | 2021 | 2258 | 0.230 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9275 | 0.220 |
Why?
|
Milk, Human | 1 | 2008 | 490 | 0.220 |
Why?
|
Herpesvirus 6, Human | 1 | 2023 | 95 | 0.220 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2009 | 1821 | 0.210 |
Why?
|
Orbit | 4 | 2001 | 426 | 0.210 |
Why?
|
Immunomodulation | 2 | 2016 | 541 | 0.210 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 222 | 0.210 |
Why?
|
Infant, Premature, Diseases | 1 | 2008 | 706 | 0.200 |
Why?
|
Virus Activation | 1 | 2023 | 319 | 0.200 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2024 | 5442 | 0.200 |
Why?
|
Single-Chain Antibodies | 2 | 2019 | 108 | 0.200 |
Why?
|
Burkitt Lymphoma | 1 | 2023 | 328 | 0.200 |
Why?
|
Tolnaftate | 1 | 2020 | 2 | 0.200 |
Why?
|
Immunologic Memory | 3 | 2021 | 1348 | 0.190 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2002 | 200 | 0.190 |
Why?
|
Graves Disease | 3 | 1999 | 242 | 0.190 |
Why?
|
Leukocytes, Mononuclear | 4 | 2022 | 1836 | 0.190 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2008 | 1320 | 0.190 |
Why?
|
Gene Transfer Techniques | 3 | 2016 | 1224 | 0.190 |
Why?
|
Inflammation | 2 | 2020 | 10634 | 0.190 |
Why?
|
HLA Antigens | 2 | 2003 | 1382 | 0.180 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 297 | 0.180 |
Why?
|
Eyebrows | 2 | 2001 | 28 | 0.180 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2020 | 122 | 0.180 |
Why?
|
Ribonucleoproteins | 2 | 2021 | 381 | 0.180 |
Why?
|
Zebrafish | 2 | 2021 | 2994 | 0.180 |
Why?
|
Philadelphia Chromosome | 1 | 2020 | 112 | 0.170 |
Why?
|
Ophthalmologic Surgical Procedures | 2 | 1999 | 349 | 0.170 |
Why?
|
Mice, SCID | 3 | 2019 | 2716 | 0.170 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2002 | 595 | 0.170 |
Why?
|
Women's Rights | 1 | 2019 | 69 | 0.170 |
Why?
|
Chemotactic Factors | 1 | 1999 | 199 | 0.170 |
Why?
|
HEK293 Cells | 4 | 2021 | 4201 | 0.170 |
Why?
|
Macrophage Activation | 1 | 2022 | 558 | 0.170 |
Why?
|
Lymphocytes | 3 | 2024 | 2617 | 0.170 |
Why?
|
Reference Standards | 1 | 2022 | 1025 | 0.160 |
Why?
|
Tumor Cells, Cultured | 5 | 2021 | 6313 | 0.160 |
Why?
|
Codon, Nonsense | 1 | 2019 | 281 | 0.160 |
Why?
|
Rhabdomyosarcoma | 1 | 2021 | 382 | 0.160 |
Why?
|
Craniotomy | 2 | 2001 | 729 | 0.160 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2018 | 77 | 0.160 |
Why?
|
Lymphoid Tissue | 1 | 2019 | 455 | 0.160 |
Why?
|
Open Reading Frames | 1 | 2021 | 810 | 0.150 |
Why?
|
Granzymes | 1 | 2019 | 271 | 0.150 |
Why?
|
Prolactin | 1 | 1999 | 669 | 0.150 |
Why?
|
Bioreactors | 1 | 2018 | 236 | 0.150 |
Why?
|
Fatal Outcome | 2 | 2019 | 1849 | 0.150 |
Why?
|
Cell Death | 2 | 2022 | 1708 | 0.150 |
Why?
|
Opportunistic Infections | 1 | 2020 | 389 | 0.150 |
Why?
|
E-Selectin | 1 | 2019 | 579 | 0.150 |
Why?
|
Gastrointestinal Tract | 1 | 2023 | 814 | 0.150 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2021 | 880 | 0.150 |
Why?
|
Protein Engineering | 3 | 2019 | 540 | 0.150 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2023 | 1860 | 0.140 |
Why?
|
Orbital Neoplasms | 1 | 1999 | 225 | 0.140 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1404 | 0.140 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2018 | 314 | 0.140 |
Why?
|
Treatment Outcome | 11 | 2019 | 63119 | 0.140 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2021 | 1380 | 0.140 |
Why?
|
Adenine | 3 | 2017 | 936 | 0.140 |
Why?
|
Interferon-gamma | 3 | 2022 | 3203 | 0.140 |
Why?
|
Immunization | 1 | 2021 | 1256 | 0.140 |
Why?
|
Melphalan | 1 | 2018 | 431 | 0.140 |
Why?
|
Biotechnology | 1 | 2018 | 280 | 0.140 |
Why?
|
Endonucleases | 1 | 2019 | 381 | 0.140 |
Why?
|
Chimerism | 2 | 2014 | 158 | 0.130 |
Why?
|
Disease Susceptibility | 2 | 2019 | 1782 | 0.130 |
Why?
|
Leukemia | 1 | 2023 | 1508 | 0.130 |
Why?
|
Skin Transplantation | 2 | 1999 | 1074 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 1434 | 0.130 |
Why?
|
Exanthema | 1 | 2019 | 501 | 0.130 |
Why?
|
Peptides | 4 | 2021 | 4407 | 0.130 |
Why?
|
HIV-1 | 3 | 2022 | 6938 | 0.130 |
Why?
|
Fever | 2 | 2019 | 1614 | 0.120 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2021 | 1366 | 0.120 |
Why?
|
Male | 28 | 2022 | 350027 | 0.120 |
Why?
|
Glaucoma, Angle-Closure | 2 | 2001 | 189 | 0.120 |
Why?
|
Antibodies, Viral | 2 | 2022 | 3176 | 0.120 |
Why?
|
Antigens, CD | 5 | 2017 | 4026 | 0.120 |
Why?
|
Adult | 22 | 2023 | 214035 | 0.120 |
Why?
|
Histiocytosis | 1 | 2014 | 39 | 0.120 |
Why?
|
Eye Diseases | 1 | 1999 | 668 | 0.120 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1275 | 0.120 |
Why?
|
Hemangioma | 1 | 1999 | 737 | 0.120 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18027 | 0.120 |
Why?
|
Eyelids | 3 | 2001 | 265 | 0.120 |
Why?
|
Sepsis | 1 | 2008 | 2593 | 0.120 |
Why?
|
Antigens, Surface | 1 | 2018 | 1663 | 0.120 |
Why?
|
Piperidines | 3 | 2017 | 1605 | 0.120 |
Why?
|
Protein Binding | 3 | 2019 | 9392 | 0.110 |
Why?
|
Physicians, Women | 1 | 2019 | 486 | 0.110 |
Why?
|
Immunoglobulin Fragments | 1 | 2013 | 84 | 0.110 |
Why?
|
Compassionate Use Trials | 1 | 2013 | 46 | 0.110 |
Why?
|
Aged | 19 | 2022 | 163253 | 0.110 |
Why?
|
Apoptosis | 5 | 2023 | 9728 | 0.110 |
Why?
|
Dependovirus | 2 | 2009 | 706 | 0.110 |
Why?
|
Surgery, Plastic | 1 | 1999 | 624 | 0.110 |
Why?
|
Induced Pluripotent Stem Cells | 2 | 2022 | 1736 | 0.110 |
Why?
|
Schools, Medical | 1 | 2019 | 878 | 0.110 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 13668 | 0.110 |
Why?
|
Cell Line | 5 | 2019 | 15999 | 0.110 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 2133 | 0.100 |
Why?
|
Disease Management | 2 | 2019 | 2458 | 0.100 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 1613 | 0.100 |
Why?
|
Glycoproteins | 1 | 2019 | 2263 | 0.100 |
Why?
|
Antigen Presentation | 3 | 2021 | 1284 | 0.100 |
Why?
|
Proteome | 1 | 2021 | 1798 | 0.100 |
Why?
|
Anterior Chamber | 2 | 2001 | 197 | 0.100 |
Why?
|
Autoimmunity | 1 | 2019 | 1349 | 0.100 |
Why?
|
Demography | 1 | 2016 | 1656 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2019 | 1415 | 0.100 |
Why?
|
HIV Infections | 3 | 2022 | 16718 | 0.090 |
Why?
|
Light Coagulation | 1 | 1990 | 72 | 0.090 |
Why?
|
Female | 27 | 2022 | 380197 | 0.090 |
Why?
|
Leadership | 1 | 2019 | 1357 | 0.090 |
Why?
|
Ocular Hypotension | 1 | 1990 | 22 | 0.090 |
Why?
|
Middle Aged | 19 | 2022 | 213367 | 0.090 |
Why?
|
Phagocytosis | 2 | 2014 | 1538 | 0.090 |
Why?
|
Melanoma | 2 | 2022 | 5475 | 0.090 |
Why?
|
Coculture Techniques | 3 | 2021 | 1341 | 0.090 |
Why?
|
Orbital Implants | 2 | 1999 | 21 | 0.090 |
Why?
|
Risk Assessment | 2 | 2022 | 23337 | 0.090 |
Why?
|
Choroid Diseases | 1 | 1990 | 66 | 0.090 |
Why?
|
Cell Aggregation | 2 | 2019 | 244 | 0.080 |
Why?
|
Organ Transplantation | 1 | 2019 | 1139 | 0.080 |
Why?
|
Immune System | 1 | 2014 | 805 | 0.080 |
Why?
|
Administration, Oral | 1 | 2016 | 3913 | 0.080 |
Why?
|
Antigens | 1 | 2014 | 1466 | 0.080 |
Why?
|
Patient Selection | 2 | 2020 | 4216 | 0.080 |
Why?
|
Muscle Proteins | 1 | 2013 | 1159 | 0.080 |
Why?
|
Biopsy | 1 | 2019 | 6757 | 0.080 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12961 | 0.070 |
Why?
|
Parvoviridae Infections | 1 | 2007 | 35 | 0.070 |
Why?
|
Receptors, Interleukin-6 | 2 | 2020 | 224 | 0.070 |
Why?
|
Critical Care | 1 | 2020 | 2644 | 0.070 |
Why?
|
Antibodies | 2 | 2014 | 2461 | 0.070 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 972 | 0.070 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2218 | 0.070 |
Why?
|
Nanoparticles | 1 | 2018 | 1905 | 0.070 |
Why?
|
Cell Movement | 1 | 2018 | 5216 | 0.070 |
Why?
|
Graft vs Host Disease | 1 | 2019 | 2957 | 0.070 |
Why?
|
Macrophages | 1 | 2021 | 5657 | 0.070 |
Why?
|
Proteins | 1 | 2021 | 6101 | 0.070 |
Why?
|
Gene Expression | 1 | 2019 | 7799 | 0.070 |
Why?
|
Protein Kinases | 1 | 2013 | 1639 | 0.070 |
Why?
|
Phenotype | 3 | 2021 | 16365 | 0.070 |
Why?
|
Cell Differentiation | 2 | 2022 | 11478 | 0.070 |
Why?
|
Capsid Proteins | 1 | 2009 | 479 | 0.070 |
Why?
|
Retrospective Studies | 7 | 2020 | 77426 | 0.070 |
Why?
|
Glioma | 1 | 2020 | 3401 | 0.070 |
Why?
|
Bacterial Proteins | 1 | 2019 | 3849 | 0.060 |
Why?
|
Hepatocytes | 2 | 2009 | 1210 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3508 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9438 | 0.060 |
Why?
|
Stem Cell Transplantation | 1 | 2014 | 1620 | 0.060 |
Why?
|
Ovarian Neoplasms | 2 | 2017 | 4837 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2023 | 39045 | 0.060 |
Why?
|
Capsid | 1 | 2007 | 436 | 0.060 |
Why?
|
Anemia | 1 | 2014 | 1504 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2016 | 5169 | 0.060 |
Why?
|
Drug Approval | 2 | 2020 | 741 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3611 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11368 | 0.060 |
Why?
|
Ligands | 2 | 2019 | 3294 | 0.060 |
Why?
|
Roseolovirus Infections | 1 | 2023 | 45 | 0.060 |
Why?
|
Transforming Growth Factor beta | 2 | 2023 | 2008 | 0.060 |
Why?
|
Glaucoma, Open-Angle | 1 | 1990 | 711 | 0.060 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2023 | 75 | 0.060 |
Why?
|
Genes, MHC Class I | 1 | 2003 | 258 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3132 | 0.050 |
Why?
|
Uveal Diseases | 1 | 2001 | 45 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3239 | 0.050 |
Why?
|
Interleukin-15 | 2 | 2018 | 184 | 0.050 |
Why?
|
Transplantation, Autologous | 2 | 2018 | 2124 | 0.050 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2021 | 88 | 0.050 |
Why?
|
Membrane Microdomains | 1 | 2002 | 203 | 0.050 |
Why?
|
Biology | 1 | 2024 | 294 | 0.050 |
Why?
|
Eye Enucleation | 2 | 1998 | 128 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2019 | 19227 | 0.050 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2023 | 442 | 0.050 |
Why?
|
Orbital Pseudotumor | 1 | 2001 | 42 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8628 | 0.050 |
Why?
|
CD40 Ligand | 1 | 2003 | 526 | 0.050 |
Why?
|
N-Acetylglucosaminyltransferases | 1 | 2022 | 171 | 0.050 |
Why?
|
Ciliary Body | 1 | 2001 | 173 | 0.050 |
Why?
|
Diterpenes | 1 | 2021 | 173 | 0.050 |
Why?
|
Myocardium | 1 | 2013 | 4776 | 0.050 |
Why?
|
Microspheres | 1 | 2003 | 777 | 0.040 |
Why?
|
Membrane Glycoproteins | 3 | 2003 | 3769 | 0.040 |
Why?
|
Caspases | 1 | 2023 | 928 | 0.040 |
Why?
|
Prosthesis Implantation | 3 | 1999 | 642 | 0.040 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2021 | 305 | 0.040 |
Why?
|
Chromones | 1 | 1999 | 154 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2003 | 881 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2004 | 1475 | 0.040 |
Why?
|
Time Factors | 3 | 2016 | 40063 | 0.040 |
Why?
|
Acidaminococcus | 1 | 2019 | 9 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 2019 | 112 | 0.040 |
Why?
|
Breast Feeding | 1 | 2008 | 1339 | 0.040 |
Why?
|
NIH 3T3 Cells | 1 | 2021 | 677 | 0.040 |
Why?
|
Genetic Vectors | 1 | 2009 | 3420 | 0.040 |
Why?
|
Cell Separation | 2 | 2002 | 1751 | 0.040 |
Why?
|
Azepines | 1 | 2021 | 336 | 0.040 |
Why?
|
Cell Polarity | 1 | 2002 | 645 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 480 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2021 | 743 | 0.040 |
Why?
|
Fucose | 1 | 2019 | 125 | 0.040 |
Why?
|
RNA, Viral | 1 | 2008 | 2902 | 0.040 |
Why?
|
Remission, Spontaneous | 1 | 2019 | 380 | 0.040 |
Why?
|
Ubiquitination | 1 | 2023 | 1011 | 0.040 |
Why?
|
Phthalazines | 1 | 2021 | 363 | 0.040 |
Why?
|
Young Adult | 3 | 2020 | 56436 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 29050 | 0.040 |
Why?
|
Interleukin-6 | 2 | 2020 | 3201 | 0.040 |
Why?
|
Mice, Inbred Strains | 1 | 2021 | 1827 | 0.040 |
Why?
|
Blepharoplasty | 1 | 1999 | 50 | 0.040 |
Why?
|
Child | 4 | 2023 | 77679 | 0.040 |
Why?
|
Ethmoid Sinus | 1 | 1998 | 58 | 0.040 |
Why?
|
Infant, Premature | 1 | 2008 | 2044 | 0.040 |
Why?
|
Mucocele | 1 | 1998 | 49 | 0.040 |
Why?
|
Frontal Sinus | 1 | 1998 | 50 | 0.040 |
Why?
|
Electroporation | 2 | 2014 | 251 | 0.040 |
Why?
|
Synthetic Biology | 1 | 2020 | 179 | 0.040 |
Why?
|
Polytetrafluoroethylene | 1 | 1998 | 233 | 0.040 |
Why?
|
Silicones | 1 | 2018 | 250 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2020 | 5076 | 0.040 |
Why?
|
Blood Proteins | 1 | 2002 | 1123 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 590 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 1999 | 319 | 0.040 |
Why?
|
Drug Synergism | 2 | 1999 | 1791 | 0.040 |
Why?
|
Myeloablative Agonists | 1 | 2018 | 218 | 0.040 |
Why?
|
Glycolysis | 1 | 2021 | 826 | 0.040 |
Why?
|
Laboratories | 1 | 2021 | 463 | 0.040 |
Why?
|
Paranasal Sinus Diseases | 1 | 1998 | 116 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2017 | 2455 | 0.040 |
Why?
|
Histocompatibility Antigens | 2 | 2009 | 471 | 0.040 |
Why?
|
C-Reactive Protein | 2 | 2020 | 3778 | 0.040 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 3646 | 0.040 |
Why?
|
Eyelid Diseases | 1 | 1999 | 155 | 0.040 |
Why?
|
Epidermal Growth Factor | 1 | 1999 | 709 | 0.040 |
Why?
|
Permeability | 1 | 2018 | 738 | 0.040 |
Why?
|
Chemotaxis | 1 | 1999 | 607 | 0.040 |
Why?
|
Alleles | 2 | 2021 | 6938 | 0.040 |
Why?
|
SOXB1 Transcription Factors | 1 | 2018 | 284 | 0.040 |
Why?
|
Animals, Genetically Modified | 1 | 2021 | 1549 | 0.030 |
Why?
|
Glycosylation | 1 | 2019 | 1126 | 0.030 |
Why?
|
Morpholines | 1 | 1999 | 573 | 0.030 |
Why?
|
Adolescent | 4 | 2021 | 85759 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2008 | 2026 | 0.030 |
Why?
|
Bone Plates | 1 | 1999 | 468 | 0.030 |
Why?
|
Cultural Diversity | 1 | 2019 | 359 | 0.030 |
Why?
|
MART-1 Antigen | 2 | 2007 | 64 | 0.030 |
Why?
|
Triazoles | 1 | 2021 | 911 | 0.030 |
Why?
|
Polyethylenes | 1 | 1998 | 285 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11074 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 1998 | 1032 | 0.030 |
Why?
|
Zebrafish Proteins | 1 | 2021 | 1004 | 0.030 |
Why?
|
Eye Movements | 1 | 1998 | 507 | 0.030 |
Why?
|
Viral Load | 1 | 2023 | 3300 | 0.030 |
Why?
|
Corneal Diseases | 1 | 2001 | 636 | 0.030 |
Why?
|
Cytoskeleton | 1 | 1999 | 1185 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2019 | 1880 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4752 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2272 | 0.030 |
Why?
|
HIV Antibodies | 1 | 2021 | 1322 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 2649 | 0.030 |
Why?
|
Risk Factors | 1 | 2020 | 72280 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6474 | 0.030 |
Why?
|
United States | 4 | 2023 | 69867 | 0.030 |
Why?
|
HLA-A Antigens | 1 | 2013 | 231 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2019 | 3144 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1583 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2014 | 57768 | 0.030 |
Why?
|
HIV Protease | 1 | 1992 | 96 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 1999 | 20817 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2022 | 6893 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2003 | 2725 | 0.030 |
Why?
|
Neoplasm Proteins | 3 | 2013 | 3703 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 1581 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2017 | 1200 | 0.030 |
Why?
|
Benzamides | 1 | 2017 | 1378 | 0.030 |
Why?
|
Pyrazines | 1 | 2017 | 1231 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 1999 | 4776 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2021 | 13817 | 0.020 |
Why?
|
Hypotension | 1 | 2017 | 880 | 0.020 |
Why?
|
Piperazines | 1 | 2021 | 2491 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2013 | 936 | 0.020 |
Why?
|
Syndrome | 1 | 2017 | 3250 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 1998 | 1387 | 0.020 |
Why?
|
Intraocular Pressure | 2 | 2001 | 1274 | 0.020 |
Why?
|
Child, Preschool | 3 | 2021 | 40992 | 0.020 |
Why?
|
Remission Induction | 1 | 2015 | 2389 | 0.020 |
Why?
|
Prostate | 1 | 2018 | 1773 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3278 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2003 | 5021 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2014 | 13096 | 0.020 |
Why?
|
Glucocorticoids | 1 | 1998 | 2108 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 4 | 2001 | 20123 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3598 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1999 | 3800 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8343 | 0.020 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2007 | 57 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 53280 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2008 | 25618 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5722 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2007 | 91 | 0.020 |
Why?
|
Solubility | 1 | 2009 | 1083 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15161 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3680 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2214 | 0.020 |
Why?
|
Epitopes | 1 | 2013 | 2571 | 0.020 |
Why?
|
Drug Resistance | 1 | 1992 | 1608 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4841 | 0.020 |
Why?
|
Cognition | 1 | 2023 | 6765 | 0.020 |
Why?
|
Pregnancy | 1 | 2008 | 29142 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11007 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12781 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 1998 | 3395 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2013 | 1677 | 0.020 |
Why?
|
Cohort Studies | 2 | 2019 | 40559 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2009 | 1801 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2017 | 9735 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2019 | 14556 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4151 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2014 | 13036 | 0.010 |
Why?
|
Indoles | 1 | 1992 | 1838 | 0.010 |
Why?
|
Protein Multimerization | 1 | 2009 | 971 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9647 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13280 | 0.010 |
Why?
|
Receptors, Fc | 1 | 2007 | 541 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 21752 | 0.010 |
Why?
|
Receptor Activator of Nuclear Factor-kappa B | 1 | 2003 | 79 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4252 | 0.010 |
Why?
|
Ultrasonography | 2 | 2001 | 5982 | 0.010 |
Why?
|
Centrifugation, Density Gradient | 1 | 2002 | 313 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19907 | 0.010 |
Why?
|
Laser Therapy | 1 | 1990 | 1072 | 0.010 |
Why?
|
Cell Fractionation | 1 | 2002 | 252 | 0.010 |
Why?
|
DNA, Recombinant | 1 | 2002 | 476 | 0.010 |
Why?
|
RANK Ligand | 1 | 2003 | 326 | 0.010 |
Why?
|
Torsion Abnormality | 1 | 2001 | 93 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 1992 | 5867 | 0.010 |
Why?
|
Escherichia coli | 1 | 1992 | 4220 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8387 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 21824 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2003 | 732 | 0.010 |
Why?
|
Histiocytes | 1 | 1998 | 103 | 0.010 |
Why?
|
Skin, Artificial | 1 | 1999 | 90 | 0.010 |
Why?
|
Ultraviolet Rays | 1 | 2003 | 1060 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 3 | 2001 | 35423 | 0.010 |
Why?
|
Exophthalmos | 1 | 1998 | 97 | 0.010 |
Why?
|
Osseointegration | 1 | 1998 | 276 | 0.010 |
Why?
|
Postoperative Complications | 4 | 2001 | 15294 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3871 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2002 | 1904 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2002 | 2700 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 4567 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 29784 | 0.010 |
Why?
|
Up-Regulation | 1 | 2002 | 4217 | 0.010 |
Why?
|
Decompression, Surgical | 1 | 1998 | 594 | 0.010 |
Why?
|
Arabinose | 1 | 1992 | 31 | 0.010 |
Why?
|
Rabbits | 1 | 1998 | 4892 | 0.010 |
Why?
|
Verapamil | 1 | 1992 | 244 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1992 | 878 | 0.010 |
Why?
|
Operon | 1 | 1992 | 363 | 0.010 |
Why?
|
Prosthesis Design | 1 | 1998 | 2110 | 0.010 |
Why?
|
Vinblastine | 1 | 1992 | 490 | 0.010 |
Why?
|
Wound Healing | 1 | 2001 | 2785 | 0.010 |
Why?
|
Collagen | 1 | 1999 | 2689 | 0.010 |
Why?
|
Vasoconstriction | 1 | 1992 | 597 | 0.010 |
Why?
|
Calcium Channels | 1 | 1992 | 622 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1992 | 2645 | 0.010 |
Why?
|
Endoscopy | 1 | 1998 | 1784 | 0.000 |
Why?
|
Fibroblasts | 1 | 1998 | 4156 | 0.000 |
Why?
|
Plasmids | 1 | 1992 | 2307 | 0.000 |
Why?
|
Blotting, Western | 1 | 1992 | 5180 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1992 | 6172 | 0.000 |
Why?
|
Base Sequence | 1 | 1992 | 12801 | 0.000 |
Why?
|
Calcium | 1 | 1992 | 5757 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1992 | 18116 | 0.000 |
Why?
|
Rats | 1 | 1992 | 24273 | 0.000 |
Why?
|